Friday, May 29, 2020 5:36:25 AM
"Scaled Back"? "Revenue Erosion" Is More Accurate.
Quarterly Revenues: CVSciences vis-a-vis Charlotte'sWeb
In mid 2018, soon after Charlotte's Web's IPO, CV Sciences' quarterly revenues were approximately 75% compared to those of Charlotte's Web.
Since then, there has been a steady and steep erosion in CV Sciences' quarterly revenues to less than 40% when compared to Charlotte's Web:
CVSI has little need to buy more raw material (European hemp paste) when its sales are tanking.
Quarterly Revenues: CVSciences vis-a-vis Charlotte'sWeb
In mid 2018, soon after Charlotte's Web's IPO, CV Sciences' quarterly revenues were approximately 75% compared to those of Charlotte's Web.
Since then, there has been a steady and steep erosion in CV Sciences' quarterly revenues to less than 40% when compared to Charlotte's Web:
CVSI CWBHF CVSI/CWBHF
$M $M
2018
Q2 12.3 17.2 72%
Q3 13.6 17.7 77%
Q4 14.2 21.5 66%
2019
Q1 14.9 21.7 69%
Q2 16.9 25.0 68%
Q3 12.6 25.1 50%
Q4 9.4 22.8 41%
2020
Q1 8.3 21.5 39%
CVSI has little need to buy more raw material (European hemp paste) when its sales are tanking.
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:10:09 PM
- CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results • ACCESS Newswire • 05/14/2026 08:00:00 PM
- CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026 • ACCESS Newswire • 05/12/2026 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
